Minimal residual disease in childhood acute lymphoblastic leukemia: Current status and challenges

Acta Haematologica

Volumn 112, Issue 1-2, 2004, Pages 34-39

  Izraeli, Shai ^a   Waldman, Dalia ^b  

^a SHEBA MEDICAL CENTER   (Israel)

^b NONE

Author keywords

Acute lymphoblastic leukemia; Childhood; FACS; Minimal residual disease; PCR

Indexed keywords

ANTIINFECTIVE AGENT; GENOMIC DNA; PREDNISONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; BLAST CELL; BONE MARROW TRANSPLANTATION; CHROMOSOME ABERRATION; CHROMOSOME STRUCTURE; CLINICAL TRIAL; CORRELATION ANALYSIS; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; LEUKEMIA CELL; MINIMAL RESIDUAL DISEASE; PHENOTYPE; PRIORITY JOURNAL; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; ROOM TEMPERATURE; SENSITIVITY ANALYSIS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

CHILD; FLOW CYTOMETRY; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; PROGNOSIS;

EID: 2642533386     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077558     Document Type: Review

References (29)

1. Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig WD, Henze G, Gadner H, Odenwald E, Riehm H: Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 2000;14:2205-2222.
2. Schrappe M, Camitta B, Pui CH, Eden T, Gaynon P, Gustafsson G, Janka-Schaub GE, Kamps W, Masera G, Sallan S, Tsuchida M, Vilmer E: Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia 2000;14:2193-2194.
3. Pui CH, Relling MV, Campana D, Evans WE: Childhood acute lymphoblastic leukemia. Rev Clin Exp Hematol 2002;6:161-180, 200-202.
4. Campana D: Determination of minimal residual disease in leukaemia patients. Br J Haematol 2003;121:823-838.
5. Cazzaniga G, d'Aniello E, Corral L, Biondi A: Results of minimal residual disease (MRD) evaluation and MRD-based treatment stratification in childhood ALL. Best Pract Res Clin Haematol 2002;15:623-638.
6. Szczepanski T, Orfao A, van der Velden VH, San Miguel JF, van Dongen JJ: Minimal residual disease in leukaemia patients. Lancet Oncol 2001;2:409-417.
7. Biondi A, Valsecchi MG, Seriu T, D'Aniello E, Willemse MJ, Fasching K, Pannunzio A, Gadner H, Schrappe M, Kamps WA, Bartram CR, van Dongen JJ, Panzer-Grumayer ER: Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group. Leukemia 2000;14:1939-1943.
8. Dworzak MN, Froschl G, Printz D, Mann G, Potschger U, Muhlegger N, Fritsch G, Gadner H: Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 2002;99:1952-1958.
9. Campana D, Coustan-Smith E: Minimal residual disease studies by flow cytometry in acute leukemia. Acta Haematol 2004;112:8-15.
10. Izraeli S, Janssen JW, Haas OA, Harbott J, Brok-Simoni F, Walther JU, Kovar H, Henn T, Ludwig WD, Reiter A, Gadner H: Detection and clinical relevance of genetic abnormalities in pediatric acute lymphoblastic leukemia: A comparison between cytogenetic and polymerase chain reaction analyses. Leukemia 1993;7:671-678.
11. Drunat S, Olivi M, Brunie G, Grandchamp B, Vilmer E, Bieche I, Cave H: Quantification of TEL-AML1 transcript for minimal residual disease assessment in childhood acute lymphoblastic leukaemia. Br J Haematol 2001;114:281-289.
12. Brüggemann M, Pott C, Ritgen M, Kneba M: Significance of minimal residual disease in lymphoid malignancies. Acta Haematol 2004; 112:111-119.
13. Shimoni A, Nagler A, Kaplinsky C, Reichart M, Avigdor A, Hardan I, Yeshurun M, Daniely M, Zilberstein Y, Amariglio N, Brok-Simoni F, Rechavi G, Trakhtenbrot L: Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using the bioView (Duet) combined morphological and cytogenetical analysis. Leukemia 2002;16:1413-1422.
14. Kaplinsky C, Trakhtenbrot L, Hardan I, Reichart M, Daniely M, Toren A, Amariglio N, Rechavi G, Izraeli S: Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhG-CSF. Bone Marrow Transplant 2003;32:31-34.
15. Trakhtenbrot L, Rechavi G, Amariglio N: The multiparametric scanning system for evaluation of minimal residual disease in hematological malignancies. Acta Haematol 2004;112:24-29.
16. Cazzaniga G, Rossi V, Biondi A: Monitoring minimal residual disease using chromosomal translocations in childhood ALL. Best Pract Res Clin Haematol 2002;15:21-35.
17. Cazzaniga G, Lanciotti M, Rossi V, Di Martino D, Arico M, Valsecchi MG, Basso G, Masera G, Micalizzi C, Biondi A: Prospective molecular monitoring of BCR/ABL transcript in children with Ph+ acute lymphoblastic leukaemia unravels differences in treatment response. Br J Haematol 2002;119:445-453.
18. Neale GA, Coustan-Smith E, Pan Q, Chen X, Gruhn B, Stow P, Behm FG, Pui CH, Campana D: Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 1999;13:1221-1226.
19. Campana D, Neale GA, Coustan-Smith E, Pui CH: Detection of minimal residual disease in acute lymphoblastic leukemia: The St Jude experience. Leukemia 2001;15:278-279.
20. van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig WD, Basso G, de Bruijn MA, Cazzaniga G, Hettinger K, van der Does-van den Berg A, Hop WC, Riehm H, Bartram CR: Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998;352:1731-1738.
21. Nyvold C, Madsen HO, Ryder LP, Seyfarth J, Svejgaard A, Clausen N, Wesenberg F, Jonsson OG, Forestier E, Schmiegelow K: Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood 2002;99:1253-1258.
22. Coustan-Smith E, Sancho J, Hancock ML, Razzouk BI, Ribeiro RC, Rivera GK, Rubnitz JE, Sandlund JT, Pui CH, Campana D: Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood 2002;100:2399-2402.
23. Marshall GM, Haber M, Kwan E, Zhu L, Ferrara D, Xue C, Brisco MJ, Sykes PJ, Morley A, Webster B, Dalla Pozza L, Waters K, Norris MD: Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemia. J Clin Oncol 2003;21:704-709.
24. Panzer-Grumayer ER, Schneider M, Panzer S, Fasching K, Gadner H: Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood 2000;95:790-794.
25. Campana D, Neale GA, Coustan-Smith E, Pui CH: Detection of minimal residual disease in acute lymphoblastic leukemia: The St Jude experience. Leukemia 2001;15:278-279.
26. Cave H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, Bakkus M, Thielemans K, Grandchamp B, Vilmer E: Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer - Childhood Leukemia Cooperative Group. N Engl J Med 1998;339:591-598.
27. Bader P, Hancock J, Kreyenberg H, Goulden NJ, Niethammer D, Oakhill A, Steward CG, Handgretinger R, Beck JF, Klingebiel T: Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia 2002;16:1668-1672.
28. Lion T, Izraeli S, Henn T, Gaiger A, Mor W, Gadner H: Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction. Leukemia 1992;6:495-499.
29. Greaves M: Silence of the leukemic clone. N Engl J Med 1997;336:367-369.